Search results
Showing 601 to 648 of 648 results for diabetes
This guideline covers assessing and treating bedwetting in people aged under 19. It aims to reduce bedwetting and the distress this causes by explaining what to ask in an assessment, what advice to provide, and which treatments are effective.
This guideline covers how to assess and monitor body weight and how to prevent someone from becoming overweight or obese before, during and after pregnancy. The aim is to help all women who have a baby to achieve and maintain a healthy weight by adopting a balanced diet and being physically active.
This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.
Depression in adults with a chronic physical health problem: recognition and management (CG91)
This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.
Implantation of an opaque intraocular lens for intractable double vision (IPG293)
Evidence-based recommendations on implantation of an opaque intraocular lens for intractable double vision. This involves replacing the clear lens of one eye with a non-transparent one to block out one of the double images.
View recommendations for IPG293Show all sections
Sections for IPG293
Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)
Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.
Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. This involves removing parts of the pancreas (islet cells) after the pancreas has been removed and inserting them into the liver to restart insulin production.
View recommendations for IPG274Show all sections
Sections for IPG274
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)
Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) for preventing flu.
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)
Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.
This guidance has been updated and replaced by NICE guideline NG28.
This guideline covers how to encourage employees to be physically active. The aim is to increase the working population’s physical activity levels.
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (IPG257)
Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.
View recommendations for IPG257Show all sections
Sections for IPG257
This guidance has been updated and replaced by NICE guideline NG3.
Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)
In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008
Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)
This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.
Type 2 diabetes foot problems: Prevention and management of foot problems (CG10)
This guidance has been updated and replaced by NICE guideline NG19.
This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).
NICE's guidance on pancreatic islet cell transplantation has now been replaced. Please go to NICE interventional procedure guidance 257 to view the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to NICE interventional procedure guidance 274 to view the full guidance on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy issued to the NHS in England, Wales, Scotland and Northern Ireland.
This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].
This guidance has been replaced by NICE technology appraisal guidance 63.
thrombosis or pulmonary embolism - To be confirmed Diabetes Guideline Updates planned and in progress Key topic
Insulin icodec for treating type 1 and type 2 diabetes TS ID 11770
Awaiting development [GID-TA11104] Expected publication date: TBC
Awaiting development [GID-TA10665] Expected publication date: TBC
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued [GID-HST10038]
Awaiting development [GID-TA10438] Expected publication date: TBC
Awaiting development [GID-TA10439] Expected publication date: TBC
In development [GID-MT538] Expected publication date: TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
Discontinued [GID-TA10375]
Discontinued [GID-TAG244]
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Discontinued [GID-TA10177]
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]
Discontinued [GID-TA10236]
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888
Awaiting development [GID-TA11377] Expected publication date: TBC
Discontinued [GID-NG10375]
All NICE products on diabetes. Includes any guidance, advice and quality standards.
Awaiting development [GID-TA10981] Expected publication date: TBC
In development [GID-TA11352] Expected publication date: 26 February 2025
In development [GID-TA11156] Expected publication date: 19 June 2024
In development [GID-TA11409] Expected publication date: 29 January 2025
In development [GID-NG10336] Expected publication date: 19 June 2025